TNON

Tenon Medical, Inc. (TNON) SWOT Analysis Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 3.2 (Weak)

The company’s negative ROIC indicates value destruction versus peers, implying capital is deployed less efficiently than stronger industrial and technology comparables.

A negative net debt to EBITDA reading suggests limited leverage burden, but peers with positive earnings still convert balance-sheet flexibility into superior strategic optionality.

No disclosed margin metrics in the provided data prevent evidence of durable pricing power, leaving TNON structurally behind peers with proven operating leverage.

The long cash conversion cycle signals working-capital intensity, which weakens reinvestment capacity relative to peers that recycle cash faster into growth.

Weaknesses

Score:

Negative ROIC is the clearest structural weakness, because it shows TNON is destroying capital while better peers compound returns through disciplined reinvestment.

Current and quick ratios below 1.0 indicate tight liquidity, leaving TNON more exposed than peers with stronger short-term balance-sheet resilience.

A cash conversion cycle above 160 days ties up cash in operations, which constrains flexibility versus peers with shorter inventory and receivables cycles.

The negative debt-to-equity figure reflects an atypical capital structure, but it does not offset weaker operating quality or improve peer-relative competitiveness.

Opportunities

Score:

Improving working-capital discipline could release cash from operations, and peers with shorter cycles show that this is a structural lever for margin and liquidity improvement.

If TNON converts its balance-sheet flexibility into higher-return projects, it could narrow the gap with peers that currently earn superior returns on invested capital.

The absence of segment concentration data leaves room for portfolio simplification or focus, which could improve strategic clarity versus more diversified peers.

Any future margin disclosure or operational improvement would be meaningful because peers with visible profitability typically command stronger positioning and investor confidence.

Threats

Score:

Peers with positive ROIC can compound capital while TNON destroys it, creating a widening structural gap in reinvestment capacity and competitive endurance.

Persistent liquidity pressure from sub-1.0 current and quick ratios raises execution risk, especially versus peers that can fund operations internally.

A prolonged cash conversion cycle increases dependence on external financing, which is a disadvantage relative to peers with faster cash generation.

Without evidence of durable margins or segment leadership, TNON remains vulnerable to better-capitalized peers that can defend share through scale and profitability.

Overall Score

Score:

TNON’s peer-relative positioning is weak because negative returns on capital and tight liquidity outweigh any balance-sheet flexibility, leaving it structurally behind stronger competitors.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Tenon Medical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →